Institution
University of Naples Federico II
Education•Naples, Campania, Italy•
About: University of Naples Federico II is a education organization based out in Naples, Campania, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 29291 authors who have published 68803 publications receiving 1920149 citations. The organization is also known as: Università degli Studi di Napoli Federico II & Naples University.
Topics: Population, Cancer, Large Hadron Collider, European Prospective Investigation into Cancer and Nutrition, Blood pressure
Papers published on a yearly basis
Papers
More filters
••
World Health Organization1, University of California, Berkeley2, Johns Hopkins University3, Centre for Mental Health4, VU University Amsterdam5, Emory University6, National Institutes of Health7, University of Düsseldorf8, University of Haifa9, Aarhus University10, University of Naples Federico II11, University of Copenhagen12, Public Health Foundation of India13, King's College London14, Schizophrenia Research Foundation15, Columbia University16, Addis Ababa University17
TL;DR: A comprehensive framework that may be useful for designing, implementing and evaluating interventions and programmes to reduce excess mortality in persons with SMD is described, incorporating lessons learned from the multilevel model of risk and the comprehensive intervention framework.
443 citations
••
TL;DR: Experimental results and sequence analysis suggest that an additional gene, males‐absent on the first (mof), encodes a putative acetyl transferase that plays a direct role in the specific histone acetylation associated with dosage compensation.
Abstract: Dosage compensation is a regulatory process that insures that males and females have equal amounts of X-chromosome gene products. In Drosophila, this is achieved by a 2-fold enhancement of X-linked gene transcription in males, relative to females. The enhancement of transcription is mediated by the activity of a group of regulatory genes characterized by the male-specific lethality of their loss-of-function alleles. The products of these genes form a complex that is preferentially associated with numerous sites on the X chromosome in somatic cells of males but not of females. Binding of the dosage compensation complex is correlated with a significant increase in the presence of a specific histone isoform, histone 4 acetylated at Lys16, on this chromosome. Experimental results and sequence analysis suggest that an additional gene, males-absent on the first (mof), encodes a putative acetyl transferase that plays a direct role in the specific histone acetylation associated with dosage compensation. The predicted amino acid sequence of MOF exhibits a significant level of similarity to several other proteins, including the human HIV-1 Tat interactive protein Tip60, the human monocytic leukemia zinc finger protein MOZ and the yeast silencing proteins SAS3 and SAS2.
443 citations
••
TL;DR: Current guidelines on cerebral venous thrombosis diagnosis and management were issued by the European Federation of Neurological Societies in 2010 are updated using a clearer and evidence‐based methodology.
Abstract: The current proposal for cerebral venous thrombosis guideline followed the Grading of Recommendations, Assessment, Development, and Evaluation system, formulating relevant diagnostic and treatment questions, performing systematic reviews of all available evidence and writing recommendations and deciding on their strength on an explicit and transparent manner, based on the quality of available scientific evidence. The guideline addresses both diagnostic and therapeutic topics. We suggest using magnetic resonance or computed tomography angiography for confirming the diagnosis of cerebral venous thrombosis and not screening patients with cerebral venous thrombosis routinely for thrombophilia or cancer. We recommend parenteral anticoagulation in acute cerebral venous thrombosis and decompressive surgery to prevent death due to brain herniation. We suggest to use preferentially low-molecular weight heparin in the acute phase and not using direct oral anticoagulants. We suggest not using steroids and acetazolamide to reduce death or dependency. We suggest using antiepileptics in patients with an early seizure and supratentorial lesions to prevent further early seizures. We could not make recommendations due to very poor quality of evidence concerning duration of anticoagulation after the acute phase, thrombolysis and/or thrombectomy, therapeutic lumbar puncture, and prevention of remote seizures with antiepileptic drugs. We suggest that in women who suffered a previous cerebral venous thrombosis, contraceptives containing oestrogens should be avoided. We suggest that subsequent pregnancies are safe, but use of prophylactic low-molecular weight heparin should be considered throughout pregnancy and puerperium. Multicentre observational and experimental studies are needed to increase the level of evidence supporting recommendations on the diagnosis and management of cerebral venous thrombosis.
443 citations
••
TL;DR: By enhancing the antioxidant ability of hepatocytes, through transgene vectors, one could counteract oxidative/nitrosative stress and, in this way, contribute to blocking the progression of liver disease.
442 citations
••
TL;DR: The treatment for CD is primarily a gluten-free diet (GFD), which requires significant patient education, motivation and follow-up, and less well-defined conditions such as non-coeliac gluten sensitivity (NCGS), gluten-sensitive neurological manifestations, such as ataxia, have been addressed.
Abstract: This guideline presents recommendations for the management of coeliac disease (CD) and other gluten-related disorders both in adults and children. There has been a substantial increase in the prevalence of CD over the last 50 years and many patients remain undiagnosed. Diagnostic testing, including serology and biopsy, should be performed on a gluten-containing diet. The diagnosis of CD is based on a combination of clinical, serological and histopathological data. In a group of children the diagnosis may be made without biopsy if strict criteria are available. The treatment for CD is primarily a gluten-free diet (GFD), which requires significant patient education, motivation and follow-up. Slow-responsiveness occurs frequently, particularly in those diagnosed in adulthood. Persistent or recurring symptoms necessitate a review of the original diagnosis, exclude alternative diagnoses, confirm dietary adherence (dietary review and serology) and follow-up biopsy. In addition, evaluation to exclude complications of CD, such as refractory CD or lymphoma, should be performed. The guideline also deals with other gluten-related disorders, such as dermatitis herpetiformis, which is a cutaneous manifestation of CD characterized by granular IgA deposits in the dermal papillae. The skin lesions clear with gluten withdrawal. Also, less well-defined conditions such as non-coeliac gluten sensitivity (NCGS) and gluten-sensitive neurological manifestations, such as ataxia, have been addressed. Newer therapeutic modalities for CD are being studied in clinical trials but are not yet approved for use in practice.
441 citations
Authors
Showing all 29740 results
Name | H-index | Papers | Citations |
---|---|---|---|
D. M. Strom | 176 | 3167 | 194314 |
Yang Gao | 168 | 2047 | 146301 |
Robert Stone | 160 | 1756 | 167901 |
Elio Riboli | 158 | 1136 | 110499 |
Barry J. Maron | 155 | 792 | 91595 |
H. Eugene Stanley | 154 | 1190 | 122321 |
Paul Elliott | 153 | 773 | 103839 |
Robert O. Bonow | 149 | 808 | 114836 |
Kai Simons | 147 | 426 | 93178 |
Peter Buchholz | 143 | 1181 | 92101 |
Martino Margoni | 141 | 2059 | 107829 |
H. A. Neal | 141 | 1903 | 115480 |
Luca Lista | 140 | 2044 | 110645 |
Pierluigi Paolucci | 138 | 1965 | 105050 |
Ari Helenius | 137 | 298 | 64789 |